Drug shortage: Morphine Sulfate Injection (MORPHINE SULFATE, MITIGO, INFUMORPH 200)
FDA lists 24 presentations as Current. Availability: Unavailable (6), Limited Availability (1), Available (17). Reason: Discontinuation of the manufacture of the drug; Demand increase for the drug. Companies: Hospira, Inc., a Pfizer Company, Hikma Pharmaceuticals USA, Inc., Piramal Critical Care Inc., Fresenius Kabi USA, LLC, Amphastar Pharmaceuticals, Inc..
- Published by source
- 2017-10-31
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Products
- Morphine Sulfate Injection MORPHINE SULFATE MITIGO INFUMORPH 200 DURAMORPH INFUMORPH 500
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Discontinuation of the manufacture of the drug
- Additional lots are scheduled to be manufactured. Product will be made available as it is released.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2017-10-31
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #895 | new | 2026-10-22 | 6ac9d91d7bd6…c9a13d | 6bc5bce651f0…52c5af |
Chain head: #1076 8ad5adc30b9b…88ce20